Business Wire

GPS Rebrands as “Thredd” to Reflect Its Unique Position as the Go to Payments Partner of Innovators Worldwide

27.4.2023 12:00:00 EEST | Business Wire | Press release

Share

Global Processing Services, a next generation global payments platform behind the leading fintechs, digital banks, and embedded finance providers across the UK, Europe, Asia, Middle East and North America, has today rebranded as “Thredd,” to reflect the company’s pivotal role in weaving together the different ‘threads’ of the global payments ecosystem to fuel the growth of electronic payments.

With a new leadership team comprising of industry veterans coupled with the backing of future-focused investors, this rebranding signals the next phase of customer partnership and product innovation to bring the aspirations of innovative payments visionaries to life.

Thredd is known for its customer-centred approach to enable payments innovators to launch new card programmes quickly, easily, and cost effectively. Thredd has created a unique niche as a hands-on, modern processor providing reliable digital payment processing capabilities, including real-time, bespoke card management tools, reporting, and world-class fraud prevention technology.

Certified by both Visa and Mastercard, and supporting debit, prepaid and credit programs, Thredd has enabled modern payments issuer processing since 2007 and has earned a reputation as a trusted, reliable and scalable platform.

Today, Thredd’s next-gen platform processes billions of transactions annually and powers over 100 customers across 44 countries and a broad range of use cases. Thredd is the processing partner of choice for an array of verticals, including digital banking, Buy Now Pay Later (BNPL), Travel, and Banking-as-a-Service (BaaS).

One of Thredd’s fastest growing customers today is “financial super app” Curve which allows customers to combine most debit, credit, and loyalty cards into one platform and a linked smart card for payments. Thredd has provided the issuer processing firepower for Curve’s platform since it was founded in 2016, supporting the innovative fintech as it has scaled to over 4 million customers, diversified its products, and expanded into international markets.

“Our rebranding to Thredd marks a new era for our company as we begin the next phase of our growth. We’ve spent the last six months building our management team with industry veterans to expand our platform capabilities and deepen our commitment to serving the needs of the most innovative fintechs and banks in the world, said Kevin Schultz, Chief Executive Officer of Thredd.

“Our new brand reflects our renewed focus on enabling our clients to create a more interconnected, accessible, and seamless payments ecosystem. With our experienced team and owners, we’re confident in our vision to bring our partnership approach to modern payments processing to innovators worldwide.”

Explaining why the name Thredd was chosen, Betsy Samuel, Chief Marketing Officer of Thredd, said: “Our clients, partners and team members have told us that we are the ultimate connector, bringing true partnership to the world of payments. This is our DNA, and we wanted a new name to reflect this special identity as well as our expanding position as a pivotal modern payments processor at the heart of the constantly evolving digital economy. We are proud to relaunch with a name which reflects our unique role and reputation as a critical ‘thread’ of the fabric in the ecosystem.”

Thredd is backed by an experienced private equity consortium with specialist experience in scaling payments-related tech businesses, including Advent International, Viking Global Investors, Temasek, and MissionOG; with institutional investors including Mastercard and Visa.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Louisa Bartoszek
Head of Communications
louisa.bartoszek@thredd.com

Cognito Media
thredd@cognitomedia.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Coolbrook Secures Business Finland Funding to Accelerate Electrification for the Global Steel Industry29.6.2026 11:00:00 EEST | Press release

Coolbrook, a transformational technology company dedicated to decarbonising heavy industry and industrial processes, has been awarded research and development funding by Business Finland to accelerate the decarbonisation of steel production. The grant supports Coolbrook’s participation in the FutSteel project, a core component of the Sustainable World through Steels ecosystem led by SSAB. Within the broader FutSteel project, Coolbrook’s project scope amounts to €5 million, of which €2.5 million is covered by grant funding awarded to Coolbrook. The funding will enable Coolbrook to further accelerate and develop its next-generation RotoDynamic Heater™ (RDH™) technology, specifically tailored for high-temperature steel industry applications. The project focuses on integrating RDH™ technology into critical stages of the steel production chain, including blast furnace processes, electrified reheating, hot-stove air pre-heating, hybrid-heating concepts, decarbonised Direct Reduced Iron (DRI)

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release

Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release

Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas

Enhertu ® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 09:30:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across three phase 2 trials, including DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02. In DESTINY-PanTumor02, Enhertu demonstrated a confirmed objective response rate (ORR) of 52.3% (95% confidence interval [CI]: 42.6-6

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye